Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2016-12-21 Declaration of Voting R…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Mandatory notification regarding exercise and trade of subscription rights and trade of shares
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly details transactions involving subscription rights, exercise of rights, purchase, and sale of shares by company directors and management (primary insiders) on a specific date (December 21, 2016). This type of mandatory disclosure concerning personal share transactions by company directors and executives falls directly under the definition of Director's Dealing. The reference to 'Mandatory notification regarding exercise and trade of subscription rights and trade of shares' and the disclosure requirements pursuant to Norwegian Securities Trading Act confirms this is an insider transaction report.
2016-12-21 English
PCI Biotech: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled 'PCI Biotech: Mandatory notification of trade' and explicitly details a transaction (subscription for new shares) by the Chairman, Hans Peter Bøhn. This type of filing reports personal share transactions by company directors or executives (insider trades). This directly matches the definition for Director's Dealing (DIRS). The document length is short (1082 chars), but the content is a direct report of a transaction, not an announcement of a report, making DIRS the most specific fit over the general RNS.
2016-12-14 English
PCI Biotech: Successful Investigational New Drug (IND) application
Regulatory Filings Classification · 100% confidence The document is a short announcement from PCI Biotech dated December 14, 2016, reporting the successful clearance of an Investigational New Drug (IND) application by the US FDA to include US patients in their Phase II clinical program for fimaporfin. This is a specific corporate update regarding regulatory progress and clinical trials, not a comprehensive financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). It details a significant event related to their product pipeline and regulatory standing. Since there is no specific category for 'IND Clearance' or 'Clinical Trial Update,' and it is a direct announcement of a material event, it best fits the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'LTR' if viewed as a report on legal/regulatory matters, but RNS is the broader fallback for non-financial, non-management specific announcements. Given the nature of FDA clearance, RNS is the most appropriate general regulatory filing category.
2016-12-14 English
Oslo Børs - The subscription rights in PCI Biotech Holding ASA the quoted company will be listed 14.12.2016
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the listing details for subscription rights (TR) related to PCI Biotech Holding ASA, including the listing date (14.12.2016), subscription period, issue price, and ratio. This content directly relates to a change in the company's capital structure or the issuance of new securities/rights associated with a financing event. This fits best under 'Capital/Financing Update' (CAP), as it details the mechanics of a rights issue, which is a financing activity.
2016-12-14 English
PCI Biotech: Commencement of subscription period
Share Issue/Capital Change Classification · 99% confidence The document is a formal letter addressed to existing shareholders regarding a 'FULLY GUARANTEED RIGHTS ISSUE'. It details the subscription period, price (NOK 7.0 per Offer Share), the mechanism involving 'Subscription Rights', and references an accompanying 'Prospectus' dated 13 December 2016. The core subject is the issuance of new shares to existing holders to raise capital. This activity directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV), but a specific capital raising event.
2016-12-14 English
PCI Biotech: Commencement of subscription period
Capital/Financing Update Classification · 98% confidence The document is titled "PCI Biotech Holding ASA RIGHTS ISSUE" and is explicitly a "SUBSCRIPTION FORM". It details the terms, procedures, pricing, allocation, and payment instructions for subscribing to new shares via a rights issue, referencing a prospectus and an Extraordinary General Meeting. This content is directly related to a capital raising or financing activity. Among the provided codes, "Capital/Financing Update" (CAP) is the most appropriate classification for documents detailing the mechanics of a rights issue or share subscription, as it involves changing the capital structure through new share issuance.
2016-12-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.